Linked research, clinical, and regulatory source pathways.
Company profile
About BeatO
BeatO (Health Arx Technologies Pvt. Ltd.) is India's leading digital health platform focused on chronic disease management, particularly diabetes and obesity. The company serves over 2 million patients through an integrated ecosystem of smart medical devices, digital therapeutics, and clinical support services. BeatO's product portfolio includes Bluetooth-connected continuous glucose monitors (CGM), smart glucometers, blood pressure monitors, and body composition scales that sync with their mobile app for real-time health tracking. The platform offers a doctor-led GLP-1 weight loss program featuring FDA-approved medications (Tirzepatide/Semaglutide), endocrinologist supervision, IIHMR-certified diet coaches, and at-home healthcare services. Their diabetes care program provides a 30-day free trial including prescribed medications, specialist doctor support, and personalized coaching. BeatO has established an exclusive partnership with Omron for blood pressure monitoring devices integrated with their app. With over 1 million device users, 100+ doctors, and 200+ coaches, BeatO combines connected medical devices, AI-powered insights, and human clinical expertise to deliver comprehensive chronic disease management. The company also operates an e-commerce platform offering diabetes-friendly foods, supplements, and lifestyle products. BeatO's clinical outcomes have been published internationally, demonstrating significant improvements in HbA1c levels and weight management for program participants.
Company description BeatO official website
Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at BeatO?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- High cholesterol
- Hypertension
- Metabolic syndrome
- Obesity
- Pre-diabetes
- Type 2 diabetes
Who it serves
- Health-conscious consumers
- Individual consumers with diabetes
- Obesity patients
- Pre-diabetic patients
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: BeatO CGM sensors, BeatO glucometers, FitScale body composition scale, Omron blood pressure monitors.
Geographic context
MarketsIndia (nationwide)
Company sourceOfficial website
Company milestones
Platform expansion
Launched India's first doctor-led GLP-1 weight loss program. Established exclusive partnership with Omron for integrated BP monitoring. Achieved 2 million+ patient base and 1 million+ device users. Published clinical outcomes in international diabetes journals.
Partnerships
Recorded partners
- IIHMR (certified diet coaches)
- Omron (exclusive partnership for BP monitors)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Predictors of first-ever major adverse cardiovascular events in newly diagnosed type 2 diabetes: a 5-year prospective cohort study.Acta diabetologica · Aug 28, 2026
Growing Older While Creating: Benefits of Artistic Practice Among Older Artists and Craftspeople.Journal of gerontological social work · Aug 26, 2026
Endoscopic enucleation of the prostate with pulsed Thulium:YAG generators: a systematic review.World journal of urology · Aug 23, 2026
Assessing the trifecta of enucleation using Magneto laser energy on different prostate volumes in real world practice, an EAU-endourology and AUSET collaboration.World journal of urology · Aug 13, 2026
Effectiveness of scabies treatments in Italy (SCAB-net): a prospective observational study.The Lancet. Infectious diseases · Jul 28, 2026
Mini-PCNL using the new Cyber Ho with Magneto technology versus thulium fiber laser: are there any differences?World journal of urology · Jul 13, 2026
Clinical validation
Clinical-trial records
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)NCT07519395 · Mentioned · RECRUITING
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLCNCT06765109 · Mentioned · RECRUITING
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaNCT06256588 · Mentioned · RECRUITING
Comparison Between Bipolar Transurethral Resection of the Prostate and Moses Assisted Holmium Laser Enucleation of the ProstateNCT06649357 · Mentioned · RECRUITING
EEAP Using Moses 2.0 Technology vs the Thulium Fiber Laser in Medium-Large ProstatesNCT06565741 · Mentioned · RECRUITING
Italian PheNotypes Obstructive Sleep Apnea StudyNCT06872242 · Mentioned · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Average HbA1c reduction of 2.16%
721 participants in published study
Average weight loss of 25%
Users who strictly adhered to program
82.9% users controlled sugar levels
100 users who adhered to BeatO Care program
63 mg/dl fasting sugar drop
Published in Diabetes Technology & Therapeutics
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from BeatO
Recent articles published on BeatO's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Chronic Disease Management & Digital Therapeutics
Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.